---
schema_version: "secwatch.filing_event.v1"
accession: "0000014272-22-000194"
form_type: "8-K"
ticker: "BMY"
cik: "0000014272"
company_name: "BRISTOL MYERS SQUIBB CO"
filed_at: "2022-10-26T23:59:59+00:00"
generated_at: "2026-06-23T00:45:35.228433+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BMY Q3 revenue $11.2B (-3% YoY), GAAP EPS $0.75, Non-GAAP $1.99

## Summary
- Revenue $11.2B, down 3% vs Q3 2021; U.S. revenue up 9% to $7.9B, international down 24% to $3.3B.
- GAAP EPS $0.75, Non-GAAP EPS $1.99; non-GAAP excludes amortization and acquired IPRD charges.
- In-line and new product portfolio grew 8% to $8.6B (13% ex-FX); Revlimid fell 28% to $2.4B.
- Completed Turning Point acquisition; FDA approved Sotyktu for plaque psoriasis in September.
- Adjusted 2022 GAAP EPS guidance; reaffirmed non-GAAP EPS guidance.

## SEC filing metadata
- accession: 0000014272-22-000194
- form_type: 8-K
- ticker: BMY
- cik: 0000014272
- company_name: BRISTOL MYERS SQUIBB CO
- filed_at: 2022-10-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/14272/000001427222000194/0000014272-22-000194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/14272/000001427222000194/bmy-20221025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000014272-22-000194
- JSON: https://secwatch.observer/filing/0000014272-22-000194.json
- Plain text: https://secwatch.observer/filing/0000014272-22-000194.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.